Other candidate genes selected for targeted sequencing validation in cases and controls have shown weak evidence of association with ovarian cancer risk for protein truncating variants in POLK, SLX4 (also known as FANCP), and FBXO10, but further studies are required to confirm this [54]. The gene discussed is SLX4; the disease is ovarian cancer.